Business
Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023
Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023 Canada NewsWire ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n VICTORIA, BC\n \n \n ,\n \n \n Sept. 6, 2023\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology, today announced that it will present a poster and an oral presentation at PAINWeek 2023, a national conference on pain for healthcare professionals, taking place on\n \n September 5-8, 2023\n \n , in\n \n Las Vegas, NV.\n \n \n \n \"PAINWeek is the largest U.S. pain conference for frontline clinicians and a high-profile opportunity for Eupraxia to present data from our Phase\n \n 2b\n \n clinical trial of EP-104IAR to an audience of practitioners in the pain space,\" said Dr.\n \n James Helliwell\n \n , CEO of Eupraxia. \"We believe these previously disclosed Phase\n \n 2b\n \n results, which are integral to our PAINWeek presentation, demonstrate that we are developing a product candidate with the potential for prolonged duration, and a compelling safety profile that may allow for repeat and bilateral dosing in patients experiencing pain due to osteoarthritis of the knee.\"\n \n \n \n Poster Title:\n \n EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate): Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in 318 Subjects with Knee Osteoarthritis\n \n \n \n Session Title:\n \n SIS-17 Scientific Abstracts (Oral Presentations)\n \n \n \n Abstract Number:\n \n PW10823\n \n \n \n Presentation Date and Time:\n \n Friday, September 8, 2023,\n \n 10:30-11:20 a.m. ET\n \n via the PAINWeek website at:\n \n \n \n https://www.painweek.org/\n \n \n \n The poster presentation will also be available on Eupraxia's website on\n \n September 8, 2023\n \n , at:\n \n \n \n https://eupraxiapharma.com/our-science/clinical-trials-and-publications/default.aspx\n \n \n \n \n \n About Eupraxia Pharmaceuticals Inc.\n \n \n \n \n Eupraxia is ...